Member Info for Aberdeenman

For those that are ignorant here... Regulatory Advantages Regulatory bodies treat drug cocrystals exactly as the pure drug: Drug substance has new physical properties only � its pharmacological activity is unchanged Therefore, drug cocrystals are applicable globally for both generic and abbreviated approval pathways US FDA Guidelines, April 2016: Cocrystals are classified as analogous to a new drug polymorph EMA Guidlines, May 2015: Cocrystals are treated as the same active substance as the original drug As the existing drugs are well known and have been around and in use for many years, having gone through many trials, the cocrystal version is deemed to be safe, and require minimal testing (24 hours tests on 12 volunteers') Very very clever, and will be very very valuable. First to market generics, with IP protection on the generic) in multi $B markets. https://nuformix.com/pipeline/cocrystal-technology/strategic-benefits/

Reduced Risk Nuformix�s approach uses existing drug molecules, with a history of safe use: No new safety data is required if staying within existing exposure limits, allowing rapid entry to both clinic and market Existing clinical data better informs decision making in future development Reduced time and cost of achieving clinical proof-of-concept and increasing success rates versus traditional biotech models NO NEW SAFETY DATA IS REQUIRED https://nuformix.com/pipeline/cocrystal-technology/strategic-benefits/

Good thing here is the idiots now turning up will make no difference. Those buying are unlikely to be the usual AIM punter anyway. This is Main Market, and will have a different type of investor. So negative or positive on here, will not make any difference LOL Many have been here, like myself, for well over a year, invested and waiting. yet to see any of the newcomers/share bashers even have a decent handle on what is happening here, if they did they would likely try and buy tomorrow AM.

Yes NFX is the new ticker

Reduced Risk Nuformix�s approach uses existing drug molecules, with a history of safe use: No new safety data is required if staying within existing exposure limits, allowing rapid entry to both clinic and market Existing clinical data better informs decision making in future development Reduced time and cost of achieving clinical proof-of-concept and increasing success rates versus traditional biotech models NO NEW SAFETY DATA IS REQUIRED https://nuformix.com/pipeline/cocrystal-technology/strategic-benefits/

For those that are ignorant here... Regulatory Advantages Regulatory bodies treat drug cocrystals exactly as the pure drug: Drug substance has new physical properties only � its pharmacological activity is unchanged Therefore, drug cocrystals are applicable globally for both generic and abbreviated approval pathways US FDA Guidelines, April 2016: Cocrystals are classified as analogous to a new drug polymorph EMA Guidlines, May 2015: Cocrystals are treated as the same active substance as the original drug As the existing drugs are well known and have been around and in use for many years, having gone through many trials, the cocrystal version is deemed to be safe, and require minimal testing (24 hours tests on 12 volunteers') Very very clever, and will be very very valuable. First to market generics, with IP protection on the generic) in multi $B markets. https://nuformix.com/pipeline/cocrystal-technology/strategic-benefits/

Already listed as NFX in my portfolio

You haven’t taken care into account placees I spoke with management and brokers on Friday, they know most are holding just like the major shareholders We shall see tomorrow Less that 24 hours to go

Remember the stock bashers on here are not invested here, or even shorting. Just here to stir up trouble, or to try deflect from the shite prophets comments about this How wrong could they get it??? Fools Why anyone would pay to read their drivel is beyong me, those that do will likely lose their money sooner or later. Serious money going to be made here by those of us lucky enough to have got in, for anyone else it will be very difficult to buy in any decent quantity

Quite funny really, the stock bashers on here. Apart from them and those of us who have been invested here for over 13 months, there is no-one else here lol And I don't think it will be those that read the LSE BB's that will put the price up here. So all pointless on their part. Those of us who have waited for this for 13 months are quite rightly excited, we have been posting on here for over a year without the stock bashers appearing. Now though, they crawl out the woodwork. But as I said doubt anything they do will make any difference. Less than 5% free float and diminishing quickly on Monday morning means they will be unable to do much. LOL it is going to be fun to see them try, but will not really matter what they do. I am going to be holding for long term. I may slice a very little at 50p in 4-6 months, if I am wrong, I am sure someone will remind me... Remember this is Main Market, not AIM, looking forward to trying to get more Monday

Think most have said be rich in a year or two, not in the morning. However this will multibag on Monday/Tuesday IMO, maybe you think that makes you rich, but not me. We shall soon see.

My sentiments entirely NorthernLad. Also the more of us that hold, then much less free float. All of the major shareholders have locked themselves in from 9 months to 15 months. Freefloat less than 5%, and will decrease very quickly Monday morning as buyers likely to keep shares. Going to be very very good.

Multi $B markets for EACH drug being produced. CEO said to me yesterday, most health services in the world buy the Generics automatically, where available, over the branded drug. That means guaranteed markets, or buy out by the branded drug owners. NFX will not be producing, but will licence and gain royalties, globally. Patents already granted for many areas, and many more to come. Going to be a monster.

That is correct. focus is on NXP001 and trials which will last a week or two (24 hours with 'volunteers', half taking medication, half placebo) and the rest analysis of data and writing it up. NPX002 is to follow later. Commercial deal will be done on NPX001, and then NPX002 follows. IF the company ever gets to the stage of commercialising NPX002, it may be bought out before. In additional pipeline of other patents and medications coming up. SO as I said earlier, trials will be complete in a couple of months and thereafter NPX001 commercialised. Huge price changing events in the pipeline. CEO said there would be strong newsflow over next few months.

have a read again, trials will be complete in a few months. Actual time for the trials is only a week or two.

Good thing here is trolls will have no stock, and as 95% plus will be very sticky (likely 99% within a few hours of opening) they will be unable to short this either. Really is no point them being here really, apart from maybe shite profits damaged ego (POS investment company with no investment lol, FOOLS)

Amit nowhere near this one. Run by world renowned scientists. read posts below.

$B+ exit here That makes this well north of 100pps Just need some patience, for the biggest gains... fireworks Monday Had initially thought maybe 12p this coming week, but as the freefloat is less than half my original estimate, I now think 20p is a possibility.

Fibrosis is a degenerative disease affecting most vital organs. Healthy tissue becomes scarred and impaired, ultimately resulting in organ failure. Fibrotic conditions (e.g. lung fibrosis) are typified by high patient mortality and are globally recognized as a major unmet medical need. Despite alarming growth rates, current treatments are either non-existent or offer marginal clinical benefits whilst causing side effects so severe that many patients elect to stop treatment. Why NXP002? NXP002 targets a key mechanistic pathway shared by many forms of fibrosis, meaning effective oral delivery of NXP002 could treat multiple fibrotic diseases. Despite demonstrable promise in several fibrotic conditions, poor oral efficacy of the currently marketed drug form means it is unable to exploit it�s full anti-fibrotic potential. Nuformix�s ongoing robust pre-clinical programme, running in parallel to Human PK studies, has demonstrated how NXP002 can safely inhibit multiple forms of fibrosis in greater depth. NXP002�s cocrystal drug form will enable consistent and efficacious oral delivery, creating the potential to treat multiple fibrotic conditions whilst removing severe treatment side effects. NXP002 is an example of Nuformix�s strategy to use an approved drug with a strong safety profile in new indications. Recognised safety and human precedence combine to reduce development risk and increase speed to clinic versus traditional biotech models. Note last two paragraphs for those unfamiliar with how this works regarding testing..... https://nuformix.com/pipeline/nxp002-fibrosis/ Going to be MASSIVE IMO

China is a massive market, with a lot of wealth. This is only going one way on Monday. Wish I had more....